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SUMMARY
Chagas disease, which is caused by the parasite Trypanosoma cruzi, affects approximately 7–8 million people in Latin
America. The drugs available to treat this disease are ineffective against chronic phase disease and are associated with toxic
side effects. Therefore, the development of new compounds that can kill T. cruzi at low concentrations is critically
important. Herein, we report the effects of a novel 3-arylideneindolin-2-one that inhibits sirtuins, which are highly
conserved proteins that are involved in a variety of physiological processes. The compoundKH-TFMDIwas tested against
the epimastigote, trypomastigote and amastigote forms ofT. cruzi, and its effects were evaluated using flow cytometry, light
and electron microscopy. KH-TFMDI inhibited the replication of T. cruzi intracellular amastigotes with an IC50 of
0·5±0·2 μM, which is significantly lower than the IC50 of benznidazole. The compound also lysed the highly infectious
bloodstream trypomastigotes (BST) with LC50 values of 0·8±0·3 μM at 4 °C and 2·5±1·1 μM at 37 °C. KH-TFMDI
inhibited cytokinesis and induced several morphological changes in the parasite, leading to its death by apoptosis and
autophagy. This study highlights sirtuins as a potential new target for Chagas disease therapy.
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INTRODUCTION
Chagas disease is caused by Trypanosoma cruzi and
affects approximately 7–8 million people in Latin
America (WHO, 2013). The currently available
chemotherapeutic agents for Chagas disease are
nifurtimox and benznidazole, both of which are
effective in the acute stage; however, their efficacy is
very limited during the later chronic stage. In
addition, both drugs demonstrate poor activity
against many T. cruzi isolates and exhibit consider-
able side effects that can lead to the discontinuation of
the therapy (Soeiro and Castro, 2011). In recent
years, several studies have been carried out to identify
selective and metabolic targets for Chagas disease
therapy. Among these, sterol biosynthesis has been
studied in some detail, and several inhibitors of this
metabolic pathway are considered the most advanced
candidate treatments, including posaconazole, which
inhibits the sterol C14-demethylase of the protozoan
(Urbina, 2010).
Class III histone deacetylases (HDACs), also
known as sirtuins, are highly conserved from
Archaea to higher eukaryotes. Todate, seven different
human sirtuins (SIRT1 to SIRT7) have been
reported. SIRT1 is involved in cell calorie restriction,
fat mobilization and the regulation of autophagic
degradation and works together with SIRT3 to
promote lifespan extension in various organisms
(Salminen and Kaarniranta, 2009; Nakagawa and
Guarente, 2011). SIRT2 is responsible for tubulin
deacetylation, while SIRT3, SIRT4 and SIRT5 are
associated with stress responses and mitochondrial
metabolism. SIRT6 is involved in DNA repair
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mechanisms, and SIRT7 activates RNA polymerase
(NakagawaandGuarente, 2011).Several sirtuinshave
been identified in the genomes of various protozoa.
Indeed, T. cruzi possesses two sirtuin-like genes,
TcSIR2rp1 and TcSIR2rp3. However, the functions
and localization of the products of these genes are
currently unknown (Religa and Waters, 2012). In
Leishmania, sirtuins are involved in the virulence and
survival of the parasite and demonstrate differential
distribution patterns during the cell cycle (Zemzoumi
et al. 1998). In the bloodstream forms ofTrypanosoma
brucei, SIRT2 localizes to the nucleus and the
mitochondria of the parasite and is involved in DNA
repair (Alsford et al. 2007).
Recently, the sirtuin pathway has been studied
extensively, and the results of these studies
have indicated that sirtuin activator/inhibitor
drugs have great potential in the treatment of several
diseases, including those caused by protozoa (Baur
et al. 2012; Zheng, 2013). Herein, we report the
effects of the novel sirtuin inhibitor KH-TFMDI,
a 3-arylideneindolin-2-one, based on a 6,7-dichloro-
2-oxindole scaffold, which showed in vitro activity
against mammalian SIRT1-3 (Huber et al. 2010). At
very low concentrations, this compound was able
to inhibit the replication of the epimastigote and
amastigote forms. In addition, KH-TFDMI caused
the lysis of the highly infective bloodstream trypo-
mastigote forms. Microscopic analysis of treated
parasites revealed significant morphological changes
that led to the interruption of cell division and the
activation of apoptosis and autophagy.
MATERIALS AND METHODS
Drug solutions
The sirtuin inhibitor KH-TFMDI (Fig. 1) was
synthesized by Huber and Bracher (Huber et al.
2010) at the Department of Pharmacy, Center for
Drug Research, Ludwig-Maximilians-University in
Munich, Germany. A stock solution of the com-
pound (10mM) was prepared in dimethyl sulfoxide
(DMSO) (Merck, Darmstadt, Germany), and the
final concentration of DMSO in the experiments
never exceeded 0·05%.
Parasites and host cell culture
All of the assays were performed using T. cruzi
epimastigotes, trypomastigotes and intracellular
amastigotes of the Y strain (TcII) (Zingales et al.
2009). Trypomastigotes were obtained from the
supernatants of previously infected LLC-MK2 cells
at 7 days post-infection. Bloodstream trypomasti-
gotes (BST) were obtained from infected Swiss CF1
mice at the peak of parasitaemia by differential
centrifugation (Meirelles et al. 1982). Epimastigotes
were cultivated in LIT medium supplemented with
10% fetal bovine serum (FBS) (GIBCO, Grand
Island, NY) (Camargo, 1964). Resident peritoneal
macrophages were obtained from Swiss CF1 mice
and cultivated in RPMI medium (GIBCO, Grand
Island, NY) supplemented with 10% FBS at 37 °C in
a 5% CO2 atmosphere.
Cytotoxicity in peritoneal macrophages
Peritoneal macrophages were obtained as previously
described and cultured for 24 h. Thereafter, the cells
were treated with KH-TFMDI (10–100 μM) and
incubated for 96 h at 37 °C. Fresh RPMI-1640
medium containing only 10% FBS was added to
untreated samples (control). To analyse the toxicity
effects, the MTS/PMS (3-(4,5-dimethyl-2-thiazolyl)-
5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt/5-methylphenazinium methyl
sulfate) assay was performed as described by
Henriques et al. (2011). The selectivity index of
KH-TFMDI was also determined based on its
activity against the trypomastigote and intracellular
amastigote forms of T. cruzi, as follows: (ratio: 50%
cytotoxic concentration [CC50] mammalian cells/
half maximal inhibitory concentration [IC50] proto-
zoans). All experiments were performed in duplicate.
The means were determined based on at least three
experiments.
Antitrypanosomal activity
For the antiproliferative assay involving the epimas-
tigote forms, 1×106 parasites mL−1 were cultivated
in LIT medium supplemented with 10% FBS. After
24 h of epimastigote growth, concentrations of 5 to
80 μM of KH TFMDI were added to the culture and
incubated for 96 h at 28 °C. Cells were collected every
24 h for cell counting in a Neubauer chamber.
Two controls consisted of LIT supplemented with
10% FBS and LIT+0·05% DMSO. Then, the cells
were allowed to adhere to the coverslips with
0·1 mgmL−1 poly-L-Lysine, fixed with Bouin’s
solution and stained with Giemsa for morphological
analysis under a Zeiss Axioplan 2 light microscope
(Oberkochen, Germany) equipped with a Color View
XS digital video camera.
To investigate the effect of KH-TFMDI on
the amastigote form, peritoneal macrophages were
Fig. 1. Chemical structure of KH-TFMDI.
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seeded as previously described and incubated with
T. cruziBST at a ratio of 10 parasites to 1macrophage
for 2 h. Non-internalized parasites were removed
by washing, and the host cells were incubated for
24 h at 37 °C to allow the full internalization and
differentiation of trypomastigotes to amastigotes.
Fresh 10%FBS–RPMI-1640medium alone (control)
or containing KH-TFMDI (0·5–10 μM) was added
to infected cells, and the cells were incubated for 96 h
at 37 °C. Infected cultures were fixed in Bouin’s
solution and stained with Giemsa. Parasite infection
was quantified under a Zeiss Axioplan light micro-
scope (Jena, Germany) equipped with a 100× lens.
The antiproliferative assay was performed as de-
scribed by Veiga-Santos et al. (2012). Infection
indexes (i.e. the percentage of infected host cells
multiplied by the average number of intracellular
amastigotes per infected host cell) were determined
by counting a total of 500 host cells and then used as
a parameter to calculate the intensity of infection
under each condition tested in the study. Drug
activity was calculated using the SigmaPlot® (version
10) program (Systat Software Inc., San Jose, CA,
USA). The results are expressed as the mean of three
independent experiments.
For bloodstream trypomastigote assays,
5×106 parasites mL−1 were incubated for 24 h at 4
and 37 °C in RPMI-1640 medium supplemented
with 90% mouse blood in the presence or absence
of KH-TFMDI at concentrations ranging from 1
to 5 μM (Silva et al. 2011). This experiment was also
performed with trypomastigotes obtained from
the supernatant of a previously infected cell line
LLC-MK2. Between 5 to 7 days after infection
protozoa were collected from the supernatants of
infected LLC-MK2 cells and incubated with fresh
RPMI-1640 medium supplemented with 0·5% FBS,
with or without KH-TFMDI (0·1 to 5 μM), for 24 h
at 37 °C under a 5% CO2 atmosphere. The concen-
tration of KH-TFMDI at which 50% of the parasites
were lysed (LC50) was calculated by counting the
cells in a Neubauer chamber. The experiment was
performed in duplicate for each of the three different
experiments.
To compare the control and treated groups in all
assays, paired t-tests and a 95% confidence interval
were applied (GraphPad Prism v.5.00 for Windows;
GraphPad Software Inc., San Diego, CA).
Flow cytometry
For flow cytometry assays, epimastigotes were treated
with 7 and 10 μM of KH-TFMDI and incubated for
96 h at 28 °C. In addition, the trypomastigotes
obtained from the supernatants of previously infected
LLC-MK2 cells were treated with 1·8 μM TFMDI
and incubated for 24 h. After treatment, the parasites
were washed, suspended in annexin V binding buffer
and incubated at room temperature for 15min with
annexin V –Alexa 488 (Dead Cell Apoptosis Kit with
Annexin V Alexa Fluor® 488 & PI; Molecular
Probes®). Propidium iodide from the same kit was
added to the samples at the moment of acquisition.
Data were collected on a BD FACSCalibur® instru-
ment controlled by CellQuest Pro® software (BD
Biosciences, San Jose, CA, USA) and analysed with
Summit 4.3® (Dako Colorado, Inc., Fort Collins,
CO, USA). Ten thousand gated events were analysed
in each sample. The values were organized in column
graphs, and statistical analysis was performed using
Student’s t-test. The values are presented as the
mean±S.E.M. The results were considered to be
significant when P<0·05.
Scanning electron microscopy (SEM)
Trypanosoma cruzi epimastigotes were incubated
with KH-TFMDI (7 μM) for 96 h at 28 °C. Try-
pomastigotes obtained from LLC-MK2 cells were
incubated with 1·8 μM of the drug for 24 h at 37 °C.
Subsequently, the samples were fixed in 2·5%
glutaraldehyde in 0·1 M phosphate buffer (pH 7·2),
processed for SEM as previously described (Veiga-
Santos et al. 2012) and observed under a Quanta
X50 Scanning Electron Microscope. Images were
obtained and processed using XTm version
4.1.1.1935 (FEI Company).
Transmission electron microscopy (TEM)
For TEM, epimastigotes were treated with
KH-TFMDI (7 μM) and incubated for 120 h.
Trypomastigotes were incubated with 1·8 μM of the
drug for 24 h. Macrophages were infected for 24 h
and subsequently treated with 1 μM of KH-TFMDI
for 96 h. After the experimental procedure, the
samples were fixed and processed as previously
described (Macedo-Silva et al. 2011). The samples
were observed under a JEOL JEM-1200EX trans-
mission electron microscope operating at 80 kV.
Fluorescence microscopy
For the fluorescence assays, epimastigotes were
treated with 10 μM KH-TFMDI and incubated for
96 h at 28 °C; macrophages were infected for 24 h and
then treated with 1 μM of KH-TFMDI for 96 h. The
samples were fixed in 4% formaldehyde, permeabi-
lized with 0·1% saponin in 3% bovine serum albumin
(BSA) in PBS (pH 8·0) for 30min at room
temperature and washed with the BSA solution
with saponin for 15min. For the autophagy assays,
cells were incubated overnight with a 1:100 dilution
of rabbit anti-LC3B antibody (Sigma). To evaluate
tubulin localization, cells were incubated for 2 h with
a 1:200 dilution of mouse anti-α tubulin antibodies.
Then, the samples were incubated with 1:400 Alexa
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Fluor 546 (red)-labelled or 1:100 Alexa Fluor 488
(green)-labelled secondary antibodies at room temp-
erature for 1 h (Molecular Probes). After rinsing in
PBS (pH 8·0) containing 3% BSA, the coverslips
were incubated with Hoechst dye for DNA staining
(Molecular Probes). The cells were observed under a
Zeiss Axioplan microscope. As a positive control for
the induction of autophagy, the epimastigotes were
treated with 0·05mgmL−1 rapamycin for 2 h prior
to the experiment.
Ethical guidelines
This study was approved by the Ethics Committee of
the Carlos Chagas Filho Biophysics Institute in the
Health Sciences Center of Rio de Janeiro Federal
University (Licence number: IBCCF106). All ani-
mals received humane care in compliance with the
Principles of Laboratory Animal Care of theNational
Society for Medical Research and the Guide for the
Care and Use of Laboratory Animals prepared by the
USA National Institutes of Health.
RESULTS
Inhibition of cell growth and the induction
of trypomastigote lysis
The sirtuin inhibitor KH-TFMDI (Fig. 1) was
tested against all forms of T. cruzi. The compound
exhibited a dose-dependent inhibitory effect on
parasite growth with IC50 values of 7±0·51 and
0·5±0·2 μM for the epimastigote and amastigote
forms, respectively (Fig. 2A and B). The IC50 of
the reference drug benznidazole, which is presently
used to treat Chagas disease, was 8±0·3 and
2·8±0·3 μM, respectively. A drastic reduction in
both the percentage of infected macrophages and
the mean number of intracellular amastigotes per cell
was also observed. All of these results were sign-
ificantly different from those of the control group at
P40·05 according to Student’s t-test.
Fig. 2. (A) Growth of the T. cruzi epimastigotes (Y strain, TcII) treated with KH-TFMDI for 96 h at 28 °C. The
parasite was cultured in the absence (control) or presence of KH-TFMDI at concentrations from 5 to 80 μM. (B) The
effect of KH-TFMDI on intracellular amastigotes. Peritoneal macrophages were infected with trypomastigotes for 2 h
and then washed and incubated with complete medium for 24 h. Then, the infected cells were treated with 0·5–10 μM
KH-TFMDI for 96 h. The infection indexes were calculated using these results. All results were significant at
P<0·0001. (C) The effects of KH-TFMDI on T. cruzi isolated from the bloodstream and on tissue culture-derived
trypomastigotes. The activity was evaluated after 24 h of treatment at 4 or 37 °C. All results were significant at P<0·05.
(D) The effect of KH-TFMDI on peritoneal macrophage viability. Peritoneal macrophages were cultured for 24 h and
then incubated with the compound (at concentrations ranging from 10–100 μM) for 96 h at 37 °C under 5% CO2. Then,
peritoneal macrophages were incubated with MTS/PMS at 37 °C for 2 to 4 h, and the absorbance read at 490 nm in a
microplate reader. (*) indicates significance at P<0·05. The bar represents the standard deviation. All experiments were
performed in triplicate, and each set of experiments was repeated at least three times.
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KH-TFMDI showed a strong lytic activity against
tissue culture-derived trypomastigotes (TCT) and
BST; indeed, approximately 50% of TCTwere killed
at a concentration of 1·6±0·18 μM at 37 °C. Against
BSTs, an LC50 of 0·8±0·3 μM at 4 °C was observed.
For comparison, crystal violet, the drug that is
currently routinely used in blood banks to control
infection by blood transfusion, has an LC50 of
11·5 μM. When the incubation was carried out at
37 °C, KH-TFMDI showed an LC50 of 2·5±1·1 μM
(Fig. 2C), while benznidazole showed an LC50
greater than 400 μM against BSTs at 37 °C (data not
shown).
Effects on host cells
The effects ofKH-TFMDI onmammalian cells were
evaluated in peritoneal macrophages after 96 h of
incubation at 37 °C via the MTS/PMS assay
(Henriques et al. 2011). The 50% cytotoxic effects
(CC50) value of KH-TFMDI in the macrophages
was 81±12 μM (Fig. 2D).
Effects on parasite structure
Epimastigotes that were incubated with 7 μM KH-
TFMDI exhibited several changes that could be
observed using light microscopy. KH-TFMDI
treatment for 96 h altered the kinetoplast shape in
45% of the parasites, interfered with the process of
cytokinesis in approximately 37% of cells, and caused
rounding of the parasite body in approximately 26%
of the parasites. In addition, KH-TFMDI caused the
detachment of the flagellum from the cell body in
approximately 70% of the epimastigotes (Table 1).
To better visualize this flagellum detachment, epi-
mastigotes treated with 7 μM KH-TFMDI for 120 h
were analysed by fluorescence microscopy using an
anti-α tubulin antibody andHoechst stain to label the
nucleus (Fig. 3).
We also used SEM and TEM to analyse the
effects of KH-TFMDI on the protozoan structure.
Untreated T. cruzi epimastigotes exhibited a
typical elongated shape with a smooth cell surface
(Supplementary Figure S1A). In contrast, parasites
treated with 7 μM KH-TFMDI for 96 h revealed
severe morphological changes in the parasite body,
such as the detachment of the parasite flagellum
and an inhibition of cytokinesis leading to the failed
separation of the newly formed protozoans. We also
observed a depression and disruption of the plasma
membrane and an intense wrinkling of the parasite
surface (Figure S1 B–D).
Figure 4A shows a section of an untreated
epimastigote highlighting different organelles, such
as the mitochondrion, nucleus, kinetoplast and
flagellum, with normal ultrastructure. Epimastigotes
treated with 7 μMKH-TFMDI for 12 h (Fig. 4B) and
24 h (Fig. 4C and D) showed a progressive loss of
kDNA compaction. In addition, the drug also
induced other morphological changes, varying from
discrete alterations to a total destruction of the
parasite, depending on the time of drug incubation.
After 48 to 96 h of incubation, we observed four main
points of cell alterations: an increase in the number of
lipid-storage bodies, an accumulation of medial
cisternae of the Golgi complex, large structures re-
sembling myelin-like figures localized near the
flagellum, and the appearance of unpacked nuclear
chromatin (Fig. 4E and G–I). In addition, well-
developed endoplasmic reticulum (ER) profiles
were observed surrounding reservosomes and lipid-
storage bodies after 72 hof treatment (Fig. 4GandH).
The treatment of intracellular amastigote forms
with KH-TFMDI also caused alterations in the
parasite plasma membrane, such as a loss of cytoplas-
mic contents, disruption of the plasma membrane,
membrane shedding, nuclear membrane detachment
and membrane convolutions, thereby completely
altering the parasite morphology (Fig. 5B–F).
Trypomastigotes treatedwith 1·8 μMKH-TFMDI
for 24 h revealed alterations similar to those observed
in epimastigotes (Supplementary Fig. S2). Note that
untreated trypomastigotes exhibited characteristic
morphology, as evidenced by SEM (Fig. S2A), and
TEM revealed that the organelles, including the
mitochondrion, nucleus, kinetoplast and flagellum,
were also normal (Fig. S2D). KH-TFMDI caused
disorganization of the parasite plasma membrane,
with bleb formation and intense wrinkling of the
cell surface (Fig. S2B and C). The drug also altered
nuclear chromatin and kDNA compaction (Fig. S2E).
Lipid body accumulation was also observed in the
trypomastigote forms (Fig. S2F).
The mechanism of killing of the parasite
Two types of observed morphological changes
provide some insight into the mechanism of parasite
death induced by KH-TFMDI. After incubation
for 12 or 24 h, the unpacking of nuclear chromatin,
which is indicative of apoptosis, was observed (Fig. 4C
and D). After 24 h of treatment with 10 μM KH-
TFMDI, approximately 92% of the epimastigotes
Table 1. Morphological alterations caused by
KH-TFMDI treatment in T. cruzi epimastigotes






Kinetoplast rounding 4·4±3·11 45±6·06
Flagellum detachment 0 70±10·21
Cytokinesis inhibition 0 37±8·56
Cell body rounding 2·5±0·7 26±12·26
a A total of 500 cells were evaluated in each group.
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were labelled with annexin V (Fig. 6A), which binds
to phosphatidylserine (PS), a phospholipid related
to apoptotic events (Lee et al. 2013). However,
no disruption of the plasma membrane was observed;
the percentage of propidium iodide (PI)-positive cells
was lower than 1% (data not shown). After 48 and
72 h of treatment, we observed a similar labelling
pattern, with 87 and 88% of treated parasites positive
Fig. 3. Immunofluorescence microscopy demonstrating flagellum detachment in treated epimastigotes (7 μM
KH-TFMDI for 120 h). The cells were labelled with anti-α-tubulin for 2 h and with an Alexa Fluor 488
(green)-labelled secondary antibody for 1 h. Hoechst stain (5 μgmL−1) was used to label the DNA (blue).
(A, B) In untreated epimastigotes, the flagellum is attached to the parasite body; (C–F) in epimastigotes treated with
KH-TFMDI, the flagellum is detached from the parasite body; (A, C, E) phase contrast images; (B, D, F) merged
images of Hoechst and α-tubulin labelling. Bars: 10 μm.
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for annexin V (Fig. 6A), and the proportion of
PI-positive parasites increased to almost 2 and 4%
(data not shown). However, after 96 h of treatment,
we observed a significant reduction in PS-positive
epimastigotes, such that only 50% of cells were PS
positive (Fig. 6A). In the case of trypomastigotes,
after 24 h of treatment with 1·8 μM KH-TFMDI, we
observed that 40% of parasites were positive for
Annexin V (Fig. 6B), and half of these parasites (20%)
were already positive for PI, indicating that apoptosis
had occurred. However, only 3% of trypomastigotes
were positive only for PI, and less than 1% of
untreated trypomastigotes were positive for PI (data
not shown). Unfortunately, all attempts to carry out
similar experiments with intracellular amastigotes
were unsuccessful (data not shown).
Analyses of epimastigotes treated for 72 and 96 h
revealed the presence of ER profiles surrounding
structures such as the reservosomes and lipid-storage
bodies (Fig. 4G and H). The obtained images are
indicative of autophagy. Autophagy was confirmed
by labelling the drug-treated epimastigotes with
an anti-LC3B antibody (i.e. to label microtubule-
associated protein light chain 3) that is widely
employed to identify autophagic structures by
fluorescence microscopy (Fig. 7). Strong labelling
of the structures was observed in treated parasites
(Fig. 7F), whereas no labelling was observed in
untreated epimastigotes (Fig. 7C). Rapamycin, a
drug that induces autophagy, was used as a positive
control at a concentration of 0·05 μgmL−1 (Fig. 7I),
demonstrating the functionality of the assay. We also
Fig. 4. TEM images of T. cruzi epimastigotes treated with 7 or 10 μM KH-TFMDI. (A) Untreated epimastigotes
exhibit organelles with normal morphology. Kinetoplast (k), nucleus (n), Golgi (CG) and flagellum (f) after 96 h of
incubation. Epimastigotes treated with 7 μM for 12 h (B) and 24 h (C, D) show an aberrant loss of kDNA compaction
inside the mitochondrion (white arrow and arrowhead); (E, F) epimastigotes treated for 48 and 72 h contain large
structures similar to myelin-like figures (black arrow). After 48 to 96 h of treatment, lipid-storage bodies (white
arrowhead) (E–I) and the accumulation of cisternae in the medial region of the Golgi complex were observed (only in E);
(G, H) in epimastigotes after 72 h of treatment, well-developed endoplasmic reticulum membranes surrounding
reservosomes, lipid-storage bodies (arrow) and abnormal nucleus condensation (star) were observed; (I) after 120 h
of treatment, autophagosome formation (large black arrow) and membranes surrounding the lipid-storage body
(white arrowhead) were observed. Bar: (A–D) 0·5 μm; (E, F) 2 μm; (G, H) 5 μm; (I) 1 μm.
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analysed the activation of autophagy in treated
intracellular amastigotes. Strong labelling of cyto-
plasmatic structures was observed in parasites treated
with KH-TFMDI for 96 h (Fig. 8D). No LC3B
labelling was observed in untreated amastigotes
(Fig. 8B).
DISCUSSION
The observations reported here clearly show that
the sirtuin inhibitor KH-TFMDI significantly
interfered with all developmental stages of T. cruzi.
Sirtuins in mammalian cells are associated with
histone deacetylation, causing heterochromatin
Fig. 5. TEM images of T. cruzi intracellular amastigotes treated with 1 μM KH-TFMDI for 96 h. (A) Untreated
intracellular amastigote: kinetoplast (k), mitochondrion (m), nucleus (n), Golgi (CG) and flagellum (f); (B) treatment
caused plasma membrane disruption (arrow) and a loss of cytoplasmic content (stars); (C, D) plasma membrane
shedding (arrow); (E) nuclear membrane detachment (arrowhead); and (F) severe alterations in the plasma membrane,
leading to convolutions and the loss of parasite plasma membrane integrity (arrow).
Fig. 6. Column graphs representing flow cytometry experiments on T. cruzi epimastigotes (A) and trypomastigotes (B).
Epimastigotes were treated with 10 μM of KH-TFMDI for 24, 48, 72 or 96 h, while trypomastigotes were treated with
1·8 μM KH-TFMDI for 24 h. After incubation, treated or control parasites were washed, resuspended in Annexin V
Binding Buffer, incubated with Annexin V/PI and analysed on a BD FACSCalibur®, as described in the Materials and
Methods section. (A) After 24 h of treatment, 92% of epimastigotes were positive for Annexin V. After 96 h of treatment,
only 40% of epimastigotes presented the same labelling pattern. (B) After 24 h of treatment, 40% of trypomastigotes were
already positive for Annexin V. Ten thousand gated events were counted from each sample. The statistical analysis
was carried out using Student’s t-test. Values are presented as the mean±S.E.M. (***) P<0·0001 (A and B) and
(*) P<0·05 (A).
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formation and transcription repression (Nakagawa
and Guarente, 2011). As previously discussed,
T. cruzi encodes two sirtuin-like genes, TcSIR2rp1
and TcSIR2rp3, but the localization and function
of the encoded proteins remain unclear (Religa and
Waters, 2012).
At very low concentrations, the sirtuin inhibitor
KH-TFMDI was able to inhibit the replication of
the epimastigote forms, which proliferate in axenic
cultures, and the amastigote form, which replicates
in the cytoplasm of host cells and is responsible for
the amplification of the infection. Interestingly, KH-
TFMDI showed better activity against intracellular
amastigotes than the reference drug benznidazole. In
addition, KH-TFDMI caused the lysis of the highly
infective bloodstream trypomastigote form and was
more active than crystal violet. Moreover, treatment
with crystal violet changes the colour of the blood to
violet, which is not well accepted by some patients.
These observations have encouraged us to initiate
further studies focusing on the use of KH-TFMDI
in blood banks.
One important criterion for potential anti-
trypanosomal drugs is a low toxicity against mam-
malian cells. Here, KH-TFMDI was found to have
significant selectivity indexes; it was 50-fold more
selective against TCT and 162-fold more selective
against intracellular amastigotes than peritoneal
macrophages. Therefore, KH-TFMDI shows prom-
ising mammalian cell tolerance indexes compared
with other drugs currently being used in clinical
therapy. The reference drug benznidazole, which is
used to treat Chagas disease, presents a CC50 value of
1218 μM in LLC-MK2 cells (Cogo et al. 2012).
However, this drug still has considerable side effects
for patients, including hypersensitivity reactions,
bone marrow depletion and peripheral polyneuro-
pathy (Soeiro and Castro, 2011).
Recently, several molecules with the ability to
inhibit/activate the deacetylase activity of sirtuins
have shown anticancer, anti-HIV, anti-protozoan,
metabolic and neurological activities (Baur et al.
2012; Zheng, 2013). Significant activities were
found in assays testing this group of drugs against
trypanosomatids. Bisnaphthalimidopropyl (BNIP),
an anti-cancer drug, also showed strong and selective
effects against the SIRT1 of Leishmania infantum
(Tavares et al. 2010). In addition, suramin, a selective
SIRT1 inhibitor with anti-proliferative effects, has
been used to treat African trypanosomiasis since the
Fig. 7. Immunofluorescence microscopy demonstrating LCB3 labelling (i.e. a marker of autophagic cell death) of
epimastigotes treated with 10 μM of KH-TFMDI. (A, C) Untreated epimastigotes after 96 h of incubation show only
Hoechst labelling; epimastigotes treated with KH-TFMDI (D–F) and rapamycin (0·05mgmL−1) (G–I) exhibit intense
red labelling (arrowhead). Bar: 5 μm.
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1920s and has also demonstrated activity against
T. cruzi. The compound caused morphological
changes in the amastigote and trypomastigote
forms, interfering with cell division and differentia-
tion processes. In addition, trypomastigotes obtained
from suramin-treated host cells were significantly
less infective than untreated parasites, and the
amastigotes derived from those trypomastigote
forms were less proliferative (Voogd et al. 1993;
Bisaggio et al. 2008). Similar antiproliferative acti-
vities were also demonstrated for the compound
sirtinol, a commercial SIRT2 inhibitor. This drug
also blocked L. infantum amastigote multiplication
and promoted cell death associated with DNA
fragmentation (Vergnes et al. 2002, 2005).
As observed using light microscopy and SEM,
KH-TFMDI inhibited cytokinesis and caused the
detachment of the parasite flagellum. The flagellum
is normally strongly attached to the cell body of
T. cruzi. Studies have suggested that the flagellum-
cell body attachment zone, known as FAZ, plays an
important role in the establishment of the protozoan
shape and in cell division by acting as a molecular
organizing centre (Kohl and Bastin, 2003). The FAZ
region also has another important function, i.e.
indicating the precise site of cell division initiation.
In cells with altered FAZ, cell separation is slowed or
completely inhibited (Kohl et al. 2003). We observed
that the separation of newly formed epimastigotes is
blocked in KH-TFMDI-treated cells.
Treatment with KH-TFMDI also induced torsion
and the rounding and thinning of the cell body in
T. cruzi. These alterations may be indicative of
the destabilization of cytoskeleton components
or microtubule-associated proteins. Taxol, an anti-
microtubule agent with activity against T. cruzi, also
demonstrated intense morphological alterations of
the parasite body that were similar to those induced
byKH-TFMDI treatment (Dantas et al. 2003). Note
that SIRT2 is a tubulin deacetylase that has the
ability to control the level of tubulin acetylation,
which affects the microtubule network (Nakagawa
and Guarente, 2011).
The activation of autophagy, apoptosis, or both has
previously been described inT. cruzi. Autophagy is a
process in which cellular components, such as the
cytoplasm, organelles and protein aggregates, are
catabolized through the formation of structures with
double membranes, known as autophagosomes. This
process can cause cell death due to the extensive
degradation of cell components or the non-selective
degradation of important structures and organelles
(Gump and Thorburn, 2011).
Because TEM findings revealed morphological
alterations of the nuclear and mitochondrial DNA of
the treated parasites, flow cytometry studies were
conducted to explore whether KH-TFMDI could
trigger programmed cell death in the epimastigote,
trypomastigote and amastigote forms. Flow cytome-
try showed that treated epimastigotes and trypomas-
tigotes were both positive for Annexin V, an early
hallmark of apoptosis-like cell death (Lee et al. 2013).
After 24, 48 and 72 h of treatment, 92, 87 and 88% of
epimastigotes were positive for Annexin V, respect-
ively. However, after 96 h of treatment, we observed a
significant reduction in the proportion of PS-positive
epimastigotes; only 50% of cells were PS positive at
this time point. This significant reduction is due to
the parasite death caused by severe morphological
changes in the parasite body. In addition to the
depression and disruption of the plasma membrane,
the drug affects the microtubule network through
events related to the capacity of sirtuins to control
tubulin acetylation (Nakagawa and Guarente, 2011).
In the case of the trypomastigotes, 20% of parasites
were positive for annexinV, 20%were double positive
for annexin V and PI, and only 3% of trypomastigotes
were positive for PI only. These data suggest that
apoptosis is the first cell death event that takes place
when epimastigotes and trypomastigotes are treated
with KH-TFMDI.
As reviewed by Verdin et al. (2010), sirtuin
inhibitors interfere directly with mitochondrial
metabolism, including energy production, signalling
events and even apoptosis. Nevertheless, the drug
also induced the activation of autophagic mechanisms
in epimastigotes and intracellular amastigotes. In a
recent study using a triazolic naphthofuranquinone,
Fernandes et al. (2012) also observed the presence
Fig. 8. Immunofluorescence microscopy of intracellular
amastigotes labelled with antibodies against LC3B
(microtubule-associated protein light chain 3), a marker
of autophagic cell death (red), and Hoechst, a nuclear
marker (blue). (A, B) Untreated infected macrophages
after 96 h: (A) Hoechst labelling; (B) no anti-LC3B
labelling was observed; (C, D) Intracellular amastigotes
treated with 1 μM KH-TFMDI: (C) Hoechst labelling,
(D) merge of Hoechst and anti-LC3B staining.
Bars = 10 μm.
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of endoplasmic ER surrounding reservosomes. These
authors also suggested that the presence of this
membrane network is associated with an increase
in monodansylcadaverine labelling, which is an
indicator of autophagy activation. We confirmed the
activation of autophagy by immunofluorescence
microscopy.
In conclusion, our results suggest that KH-
TFMDI impairs epimastigote and amastigote
proliferation by causing drastic alterations in the
ultrastructure of T. cruzi and induces the activation
of apoptosis and autophagy mechanisms that lead to
cell death. In addition, KH-TFMDI also showed
important trypanosomicidal activity against BTs.
Collectively, the results of the present study indicate
that sirtuin inhibitors are potential new compounds
for the treatment of Chagas disease and blood control
in blood banks.
SUPPLEMENTARY MATERIAL
To view supplementary material for this article, please visit
http://dx.doi.org/S0031182013001704.
ACKNOWLEDGEMENTS
The authors thank Luzinete da Silva and Rachel Rachid for
their technical assistance and CristinaHenriques and Emile
Barrias for their help with the animals.
FINANCIAL SUPPORT
This work was supported by the Conselho Nacional
de Desenvolvimento Cientifico e Tecnológico (CNPq),
Financiadora de Estudos e Projetos (FINEP), Fundação de
Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
and Fundação Carlos Chagas Filho de Amparo a Pesquisa
do Estado do Rio de Janeiro (FAPERJ).
REFERENCES
Alsford, S., Kawahara, T., Isamah, C. and Horn, D. (2007). A sirtuin in
the African trypanosome is involved in both DNA repair and telomeric gene
silencing but is not required for antigenic variation. Molecular Microbiology
63, 724–736. doi: 10.1111/j.1365-2958.2006.05553.x.
Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G. and Cabo, R.
(2012). Are sirtuins viable targets for improving healthspan and lifespan?
Nature Review Drug Discovery 11, 443–461. doi: 10.1038/nrd3738.
Bisaggio, D. F. R., Adade, C.M. and Souto- Padrón, T. (2008). In vitro
effects of suramin on Trypanosoma cruzi. International Journal of
Antimicrobial Agents 31, 282–286. doi: 10.1016/j.ijantimicag.2007.11.001.
Camargo, E. P. (1964). Growth and differentiation in Trypanosoma cruzi.
Origin of metacyclic trypanosomes in liquid media. Revista do Instituto de
Medicina tropical de São Paulo 6, 93–100.
Cogo, J., Caleare, A. O., Ueda-Nakamura, T., Dias Filho, B. P.,
Ferreira, I. C. P. and Nakamura, C. V. (2012). Trypanocidal activity of
guaianolide obtained from Tanacetum parthenium (L.) Schultz-Bip. and its
combinational effect with benznidazole. Phytomedicine 1, 59–66. doi:
10.1016/j.phymed.2012.09.011.
Dantas, A. P., Barbosa, H. S. and De Castro, S. L. (2003). Biological
and ultrastructural effects of the anti-microtubule agent taxol against
Trypanosoma cruzi. Journal of Submicroscopic Cytology and Pathology 35,
287–294.
Fernandes, M. C., Da Silva, E. N., Jr., Pinto, A. V., De Castro, S. L.
and Menna-Barreto, R. F. S. (2012). A novel triazolic naphthofuranqui-
none induces autophagy in reservosomes and impairment of mitosis
in Trypanosoma cruzi. Parasitology 139, 26–36. doi: 10.1017/
S0031182011001612.
Gump, J.M. and Thorburn, A. (2011). Autophagy and apoptosis: what
is the connection? Trends in Cell Biology 21, 387–392. doi: 10.1016/j.tcb.
2011.03.007.
Henriques, C., Moreira, T. L. B., Maia-Brigagão, C., Henriques-
Pons, A., Carvalho, T.M. U. and De Souza, W. (2011). Tetrazolium
salts based methods for high-throughput evaluation of anti-parasite
chemotherapy. Analytical Methods 3, 2148–2155.
Huber, K., Schemies, J., Uciechowska, U., Wagner, J.M., Rumpf, T.,
Lewrick, F., Süss, R., Sippl, W., Jung,M. and Bracher, F. (2010). Novel
3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone
deacetylases (sirtuins). Journal of Medicinal Chemistry 53, 1383–1386. doi:
10.1021/jm901055u.
Kohl, L. and Bastin, P. (2003). The flagellum of trypanosomes.
International Review of Cytology 244, 227–285.
Kohl, L., Robinson, D. and Bastin, P. (2003). Novel roles for the flagellum
in cell morphogenesis and cytokinesis of trypanosomes. EMBO Journal 22,
5336–5346.
Lee, S. H., Meng, X.W., Flatten, K. S., Loegering, D. A.
and Kaufmann, S. H. (2013). Phosphatidylserine exposure during
apoptosis reflects bidirectional trafficking between plasma membrane and
cytoplasm. Cell Death and Differentiation 20, 64–76. doi: 10.1038/
cdd.2012.93.
Macedo-Silva, S. T., Silva, T. L. A. O., Urbina, J. A., De Souza, W.
and Rodrigues, J. C. F. (2011). Antiproliferative, ultrastructural, and
physiological effects of amiodarone on promastigote and amastigote
forms of Leishmania amazonensis. Molecular Biology International 876021.
doi: 10.4061/2011/876021.
Meirelles, M.N., De Araújo Jorge, T. C. and De Souza, W. (1982).
Interaction of Trypanosoma cruzi with macrophages in vitro: dissociation of
the attachment and internalization phases by low temperature and
cytochalasin B. Zeitschrift für Parasitenkunde 68, 7–14.
Nakagawa, T. and Guarente, L. (2011). Sirtuins at a glance. Journal of
Cell Science 124, 833–838. doi: 10.1242/jcs.081067.
Religa, A. A. and Waters, A. P. (2012). Sirtuins of parasitic protozoa: in
search of function(s). Molecular and Biochemical Parasitology 185, 71–88.
doi: 10.1016/j.molbiopara.2012.08.003.
Salminen, A. and Kaarniranta, K. (2009). SIRT1: regulation of
longevity via autophagy. Cellular Signalling 21, 1356–1360. doi: 10.1016/
j.cellsig.2009.02.014.
Soeiro, M.N. C. and Castro, S. L. (2011). Screening of potential anti-
Trypanosoma cruzi candidates: in vitro and in vivo studies. Open Medicinal
Chemistry Journal 5, 21–30. doi: 10.2174/1874104501105010021.
Silva, C. F., Daliry, A., Bernardino, P., Silva, P. B., Akay, S.,
Banerjee, B., Farahat, A. A., Fisher, M., Hu, L., Kumar, A., Liu, Z.,
Stephens, C. E., Boykin, D. and Soeiro, M.N. C. (2011). The efficacy of
novel arylimidamides against Trypanosoma cruzi in vitro. Parasitology 138,
1863–1869.
Tavares, J., Ouaissi, A., Kong Thoo Lin, P., Loureireo, I., Kaur, S.,
Roy, N. and Cordeiro-Da-Silva, A. (2010). Bisnaphthalimidopropyl
derivatives as inhibitors of Leishmania SIR2 related protein 1.
ChemMedChem 5, 140–147.
Urbina, J. A. (2010). New insights in Chagas’ disease treatment.Drugs of the
Future 35, 409–419. doi: 10.1358/dof.2010.35.5.1484391.
Veiga-Santos, P., Barrias, E. S., Santos, J. F. C., Moreira, T. L. B.,
Carvalho, T.M. U. and De Souza, W. (2012). Effects of amiodarone and
posaconazole on the growth and ultrastructure of Trypanosoma cruzi.
International Journal of Antimicrobial Agents 40, 61–71. doi: 10.1016/j.
ijantimicag.2012.03.009.
Verdin, E., Hirschey, M. D., Finley, L.W. S. and Haigis, M. C. (2010).
Sirtuin regulation of mitochondria: energy production, apoptosis, and
signaling. Trends in Biochemical Sciences 35, 669–675. doi: 10.1016/j.
tibs.2010.07.003.
Vergnes, B., Sereno, D., Madjidian-Sereno, N., Lemesre, J. L. and
Ouaissi, A. (2002). Cytoplasmic SIR2 homologue overexpression promotes
survival of Leishmania parasites by preventing programmed cell death.Gene
296, 139–150. doi: 10.1016/S0378-1119(02)00842-9.
Vergnes, B., Vanhille, L., Ouaissi, A. and Sereno, D. (2005). Stage-
specific antileishmanial activity of an inhibitor of SIR2 histone deacetylase.
Acta Tropica 94, 107–115. doi: 10.1016/j.actatropica.2005.03.004.
Voogd, T. E., Vansterkenburg, E. L.M., Wilting, J. and
Janssen, L. H.M. (1993). Recent research on the biological activity of
suramin. Pharmacological Reviews 46, 177–199.
Zemzoumi, K., Sereno, D., Francois, C., Guilvard, E., Lemesre, J. L.
and Ouaissi, A. (1998). Leishmania major: cell type dependent distribution
of a 43 kDa antigen related to silent information regulatory-2 protein family.
Biology of the Cell 90, 239–245.
824Phercyles Veiga-Santos and others
https://doi.org/10.1017/S0031182013001704
Downloaded from https://www.cambridge.org/core. UB der LMU München, on 26 Nov 2018 at 13:32:36, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
Zheng, W. (2013). Sirtuins as emerging anti-parasitic targets. European
Journal of Medicinal Chemistry 59, 132–140. doi: 10.1016/j.ejmech.2012.
11.014.
Zingales, B., Andrade, S. G., Briones, M. R. S., Campbell, D. A.,
Chiari, E., Fernandes, O., Guhl, F., Lages-Silva, E., Macedo, A.M.,
Machado, C. R., Miles, M. A., Romanha, A. J., Sturm, N. R.,
Tibayrenc, M. and Schijman, A. G. (2009). A new consensus for
Trypanosoma cruzi intraspecific nomenclature: second revision meeting
recommends TcI to TcVI. Memórias do Instituto Oswaldo Cruz 104, 1051–
1054.
World Health Organization (2013). Control of Chagas Disease. Fact
sheet No 340 Updated March 2013. World Health Organization, Geneva,
Switzerland.
825Antitrypanosomal activity of KH-TFMDI
https://doi.org/10.1017/S0031182013001704
Downloaded from https://www.cambridge.org/core. UB der LMU München, on 26 Nov 2018 at 13:32:36, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
